

Lloyds Banking Group plc  
 Form 424B5  
 January 09, 2013

CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities Offered	Maximum Aggregate Offering Price	Amount of Registration Fee(1)
Debt Securities	\$174,000.00	\$23.73
Guarantee of Debt Securities	-	-(2)
Total	\$174,000.00	\$23.73

(1) Calculated in accordance with Rule 457(r)

(2) Pursuant to Rule 457(n), no separate fee is payable with respect to the guarantee

Pricing Supplement No. 90 (To Prospectus Supplement dated November 25, 2011 and Prospectus dated December 22, 2010)	Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-167844 and 333-167844-01 January 7, 2013
---	---

CUSIP/ ISIN	Aggregate Principal Amount	Price to Public(1)	Selling Agent's Commission(2)	Net Proceeds	Interest Type	Interest Rate	Interest Payment Frequency	Day Count Fraction	B Co Fol una Ne and
53944XDT9/ US53944XDT90	\$174,000.00	\$1,000.00	\$13.50	\$986.50	Fixed	3.00% per annum	Semi-annually	30/360	
	Per Note:	\$1,000.00	\$13.50	\$986.50					
	Total:	\$174,000.00	\$2,349.00	\$171,651.00					

Redemption Information: Non-Callable

Selling Agent: Barclays Capital Inc.

(1) The proceeds you might expect to receive if you were able to resell the Notes on the Issue Date are expected to be less than the issue price. This is because the issue price includes the selling agent's commission set forth above and also reflects certain hedging costs associated with the Notes. For additional information, see "Risk Factors — The issue price of the notes has certain built-in costs, including the selling agent's commission and our cost of hedging, both of which are expected to be reflected in secondary market prices" on page S-3 of the accompanying prospectus supplement. The issue price also does not include fees that you may be charged if you buy the Notes through your registered investment advisers for managed fee-based accounts.

(2) The Selling Agent may retain all or a portion of this commission or use all or a portion of this commission to pay selling concessions or fees to other dealers. See "Supplemental Plan of Distribution" on page S-26 of the accompanying prospectus supplement.

Lloyds TSB Bank plc	Offering Dates: December 21, 2012 through January 7, 2013	Notes: Retail Notes, Series B
	Trade Date: January 7, 2013	Issuer: Lloyds TSB Bank plc ("Lloyds Bank")
	Issue Date: January 10, 2013	Guarantor: Lloyds Banking Group plc ("LBG")
	Date:	

fully and Minimum Denomination/Increments: \$1,000/\$1,000  
unconditionally Settlement and Clearance: DTC; Book-Entry  
guaranteed by Listing: The Notes will not be listed or displayed on any securities exchange or quotation system.

Lloyds Banking Survivor's Option Payment Date: Subject to limitations, each February 15 and August 15 of each  
Group plc calendar year. See "Risk Factors — Any Survivor's Option may be limited in amount, and any repayments  
made with respect to the exercise of a Survivor's Option will not be made immediately" and "Description  
Retail Notes, of the Survivor's Option" starting on page S-6 and page S-17, respectively, in the accompanying  
Series B prospectus supplement.

Interest Payment Dates: Interest on the Notes will be paid semi-annually in arrears on the 10th day of  
each January and July (each an "Interest Payment Date") beginning on (and including) July 10, 2013 and  
ending on the Maturity Date or the Survivor's Option Payment Date, if applicable. For additional  
information see "Description of the Notes and the Guarantees — Payment of Principal, Interest and Other  
Amounts Due" starting on page S-10 in the accompanying prospectus supplement.

If an Interest Payment Date, the Maturity Date or the Survivor's Option Payment Date, if applicable, for  
any Note is not a business day (as defined in the accompanying prospectus supplement), principal,  
premium, if any, and interest for that Note will be paid on the next business day, and no additional  
interest will accrue in respect of such payments made on the next business day.

In the opinion of Davis Polk & Wardwell LLP, when the notes offered by this pricing supplement have  
been executed and issued by the Issuer and the Guarantor and authenticated by the trustee pursuant to  
the Indenture, and delivered against payment as contemplated herein, such notes will constitute valid  
and binding obligations of the Issuer, and the related guarantee will constitute a valid and binding  
obligation of the Guarantor, in each case enforceable in accordance with their terms, subject to  
applicable bankruptcy, insolvency and similar laws affecting creditors' rights generally, concepts of  
reasonableness and equitable principles of general applicability. This opinion is given as of the date  
hereof and is limited to the laws of the State of New York. Insofar as this opinion involves matters  
governed by Scots law, Davis Polk & Wardwell LLP has relied, without independent inquiry or  
investigation, on the opinion of Dundas & Wilson CS LLP, dated December 20, 2012 and filed by the  
Guarantor as an exhibit to a Report on Form 6-K on December 20, 2012. Insofar as this opinion  
involves matters governed by English law, Davis Polk & Wardwell LLP has relied, without independent  
inquiry or investigation, on the opinion of Linklaters LLP, dated December 20, 2012 and filed by the  
Guarantor as an exhibit to a Report on Form 6-K on December 20, 2012. The opinion of Davis Polk &  
Wardwell LLP is subject to the same assumptions, qualifications and limitations with respect to such  
matters as are contained in the opinions of Dundas & Wilson CS LLP and Linklaters LLP. In addition,  
the opinion of Davis Polk & Wardwell LLP is subject to customary assumptions about the  
establishment of the terms of the notes, the trustee's authorization, execution and delivery of the  
Indenture and its authentication of the notes, and the validity, binding nature and enforceability of the  
Indenture with respect to the trustee, all as stated in the opinion of Davis Polk & Wardwell LLP dated  
December 20, 2012, which was filed by the Guarantor as an exhibit to a Report on Form 6-K on  
December 20, 2012.

Any payments due on the Notes, including any repayment of principal, will be subject to the  
creditworthiness of Lloyds Bank, as the Issuer, and LBG, as the Guarantor of the Issuer's obligations  
under the Notes.

LBG and Lloyds Bank have filed a registration statement with the SEC for the offering to which this  
pricing supplement relates. Before you invest, you should read this pricing supplement together with  
the prospectus dated December 22, 2010 (the "prospectus") in that registration statement and other

Edgar Filing: Lloyds Banking Group plc - Form 424B5

documents, including the more detailed information contained in the prospectus supplement dated November 25, 2011 (the “prospectus supplement”), that LBG and Lloyds Bank have filed with the SEC for more complete information about LBG and Lloyds Bank and this offering. You may access these documents on the SEC website at [www.sec.gov](http://www.sec.gov). LBG’s Central Index Key, or CIK, on the SEC website is 1160106 and Lloyds Bank’s CIK on the SEC website is 1167831. The prospectus supplement and the prospectus may be accessed as follows (or if such address has changed, by reviewing LBG’s and Lloyds Bank’s filings for the relevant date on the SEC website):

· prospectus supplement dated November 25, 2011 and prospectus dated December 22, 2010:  
[http://www.sec.gov/Archives/edgar/data/1160106/000095010311004966/dp27400\\_424b3.htm](http://www.sec.gov/Archives/edgar/data/1160106/000095010311004966/dp27400_424b3.htm)

Investing in the Notes involves significant risks. See “Risk Factors” beginning on page S-3 of the accompanying prospectus supplement.

The Notes are not bank deposits and are not insured or guaranteed by the Federal Deposit Insurance Corporation or any other governmental agency.

None of the Securities and Exchange Commission, any state securities commission and any other regulatory body has approved or disapproved of these Notes or passed upon the adequacy or accuracy of this pricing supplement, the accompanying prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

---

January 7, 2013

---